News from akero therapeutics, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Nov 12, 2020, 16:05 ET Akero Therapeutics Reports Third Quarter 2020 Financial Results

Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designed to...

Oct 21, 2020, 16:05 ET Akero Therapeutics To Present At Upcoming Conferences In November

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with...

Oct 16, 2020, 07:30 ET Akero Therapeutics Receives European Medicines Agency Priority Medicines (PRIME) Designation for Efruxifermin (EFX) in NASH

Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designed to...

Oct 02, 2020, 07:30 ET Akero Therapeutics To Present Data From Phase 2a BALANCED Study Of Efruxifermin In NASH Patients In Presidential Plenary Talk At The Liver Meeting® 2020

Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designed to...

Sep 30, 2020, 08:00 ET Akero Therapeutics Completes Enrollment of Cohort of Cirrhotic (F4) Patients In Ongoing Balanced Study

Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designed to...

Sep 28, 2020, 16:05 ET Akero Therapeutics to Present at H.C. Wainwright's 4th Annual NASH Virtual Investor Conference

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with...

Sep 24, 2020, 07:30 ET Akero Therapeutics To Continue Efruxifermin Development With Innovative Adaptive Phase 2b/3 Clinical Trial Design Based On FDA Written Guidance

Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designed to...

Sep 09, 2020, 16:05 ET Akero Therapeutics To Present At Morgan Stanley's 18th Annual Global Healthcare Conference

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with...

Aug 12, 2020, 16:05 ET Akero Therapeutics Reports Second Quarter 2020 Financial Results

Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designed to...

Jul 21, 2020, 11:00 ET Research Published in Cell Reports Medicine Highlights Potential of Akero Therapeutics' NASH Therapeutic Candidate

Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic, non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designed to ...

Jul 10, 2020, 16:05 ET Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designed to...

Jul 07, 2020, 20:15 ET Akero Therapeutics Announces Pricing of Public Offering of Common Stock

Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designed to...

Jul 06, 2020, 07:00 ET Akero Therapeutics Announces Proposed Public Offering of Common Stock

Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designed to...

Jun 30, 2020, 16:05 ET Akero Announces Strongly Positive Histological Data Across All Efruxifermin Dose Groups in 16-Week Phase 2a BALANCED Study in NASH Patients

Akero Therapeutics, Inc. (Nasdaq: AKRO) today announced results of a 16-week analysis of secondary and exploratory endpoints in its Phase 2a BALANCED ...

Jun 29, 2020, 16:05 ET Akero Therapeutics to Announce New Data from NASH Phase 2a BALANCED Study of AKR-001

Akero Therapeutics, Inc. (Nasdaq: AKRO) today announced that the company plans to discuss new efficacy and safety data, including biopsy results,...

Jun 17, 2020, 08:00 ET Akero Therapeutics Doses First Patient in Expansion of Phase 2a Trial in NASH

Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designed to...

Jun 10, 2020, 08:00 ET Akero Therapeutics Appoints Tom Heyman to its Board of Directors

Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designed to...

May 26, 2020, 16:05 ET Akero Therapeutics To Present At The Jefferies Virtual Healthcare Conference

Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designed to...

May 13, 2020, 16:05 ET Akero Therapeutics Reports First Quarter 2020 Financial Results

Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designed to...

Mar 31, 2020, 06:00 ET All AKR-001 Dose Groups Met Week 12 Efficacy Endpoints in NASH Phase 2a BALANCED Study

Akero Therapeutics, Inc. (Nasdaq: AKRO) today announced that all three AKR-001 dose groups in the BALANCED study met the primary endpoint of absolute ...

Mar 30, 2020, 16:05 ET Akero Therapeutics to Announce Results for Week 12 Efficacy Endpoints from NASH Phase 2a BALANCED Study of AKR-001

Akero Therapeutics, Inc. (Nasdaq: AKRO) today announced that the company plans to discuss the primary endpoint and other Week 12 efficacy endpoint...

Mar 16, 2020, 07:30 ET Akero Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results

Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) Company developing pioneering medicines designed to...

Jan 13, 2020, 08:00 ET Akero Therapeutics Expands Phase 2a Trial in NASH to Include Cohort of Cirrhotic Patients

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with...

Jan 08, 2020, 16:05 ET Akero Therapeutics To Present At The 2020 J.P. Morgan Healthcare Conference

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with...

Dec 16, 2019, 16:05 ET Akero Therapeutics Completes Enrollment in Phase 2a Study in NASH

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with...